阿司匹林在川崎病治疗中的儿科专家共识

Pediatric expert consensus on the application of aspirin in Kawasaki disease

摘要:

川崎病（Kawasaki disease，KD）是5岁以下儿童常见后天获得性心脏病之一，是一种急性全身性血管炎。经过近60年的研究，静脉注射免疫球蛋白（intravenous immunoglobulin，IVIG）联合阿司匹林（aspirin，Asp）口服成为急性期KD预防冠状动脉病变（coronary artery lesion，CAL）的一线治疗。然而，Asp的作用和最佳剂量仍然存在争议。该共识基于KD治疗的国内外最新的研究成果，并经过国内儿科专家充分讨论而制定，对Asp在KD中一线治疗的使用剂量、用法、疗程等提出了推荐意见。

Abstract:

Kawasaki disease (KD) is one of the common acquired heart diseases in children aged <5 years and is an acute systemic vasculitis. After nearly 60 years of research, intravenous immunoglobulin combined with oral aspirin has become the first-line treatment for the prevention of coronary artery lesion in acute KD; however, there are still controversies over the role and optimal dose of aspirin. The consensus was formulated based on the latest research findings of KD treatment in China and overseas and comprehensive discussion of pediatric experts in China and put forward recommendations on the dose, usage, and course of aspirin treatment in the first-line treatment of KD.